secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001437749-26-010140
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva reports FY2025 net loss of $19.9M; FDA requires second Phase 3 trial for schizophrenia drug
--------------------------------------------------------------------------------

- Net loss of $19.9M ($5.48 per share) vs $29.9M ($17.73) in FY2024.
- Cash and equivalents $14.4M at Dec 31, 2025; ~$23M after March 2026 offering, funding into Q1-2027.
- FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia; initiation planned mid-2026.
- Positive 1-year open-label extension data: sustained efficacy, benign weight gain (~1.5 kg), no motor side effects.
- Completed public offerings totaling $29M in 2025 and early 2026; intends to fund RECOVER-2 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/0001437749-26-010140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/rvph20260313_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer